ERBB2 and breast cancer: Similar results were also shown in the study of Farzad et al. (2019), where another HER-2-derived peptide conjugated with liposomes increased CTL reactions, resulting in a lower tumor size and higher survival time in the vaccinated group of a murine mammary cancer model [220].